Revenue Increases 568% Year-over-Year and 78% Sequentially to $4.94 Million Q3 2025 Net Income Reaches $65.59 Million Driven by Ethereum Accumulation ETH Holdings Increased to 70,322, Valued at $291.58 Million as of 9/30/25 Launched Imperium and Successfully Integrated Aave to Extend BTCS’ Ethereum-First Strategy into Decentralized Finance WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced record revenue for the three and nine months ended September 30, 2025 (“Q3 2025”). The Company also released an updated investor presentation available at www.btcs.com/investors/. “BTCS is defining the future of Ethereum infrastructure,” said Charles Allen, CEO of BTCS. “Our 2025 third quarter...

– Revenue of $6.4 million, 22% growth – Gross margin of 32% – Adjusted EBITDA margin of -3% due to a write-off – Successful entry into renewables – First Contracts in Brazil HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its third quarter 2025 results. “We increased revenue by 22% this quarter; KOIL Energy is growing again,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “During the quarter KOIL Energy generated revenues of $6.4 million. These are clear indicators of strengthening demand both within services and products.” Third Quarter 2025 Results: For the three months ending September 30, 2025, Koil Energy generated revenues...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V, PVF.A) announced today its financial results for the nine months ended September 30, 2025. All amounts are stated in U.S. dollars. The Company recorded a net loss of $2.2 billion for the three months ended September 30, 2025, compared to a net loss of $1.2 billion in the prior year quarter. The increase in net loss was primarily due to current period remeasurement losses associated with the Company’s retractable common shares of $1.9 billion in the current quarter compared to remeasurement losses of $1.1 billion in the prior year quarter, remeasurement losses on warrants of $252 million in the current quarter compared to remeasurement losses of $114 million in the prior year quarter, and remeasurement losses on...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”, TSX: PVF.UN TSX: PVF.PR.U) announced today its financial results for the nine months ended September 30, 2025. All amounts are stated in U.S. dollars. The Partnership recorded net income of $27.1 million for the quarter ended September 30, 2025, compared to $14.6 million in the prior year quarter. The increase in income was primarily due to higher investment valuations gains, favorable foreign currency movements as a result of the depreciation of the Canadian dollar against the U.S. dollar and lower tax expense as compared to the prior year quarter. Income of $24.7 million was attributable to the Equity Limited Partners, and income of $2.4 million was attributable to Preferred Limited Partners. On August 8, 2025, the Partnership completed...

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 – $6 million PIPE financing and a proposed Daewoong note exchange – are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and...

GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We continue to achieve meaningful milestones on our path toward U.S. Food and Drug Administration (FDA) approval and eventual commercialization of AD04, our lead investigational drug, a serotonin-3 receptor antagonist being developed for the treatment of Alcohol Use Disorder (AUD). A key highlight of our recent progress was the successful End of Phase 2 (EOP2) meeting with the FDA, where we received valuable guidance...

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Sow Good Inc. (Nasdaq: SOWG) (“Sow Good” or “the Company”), a leading freeze-dried food and candy manufacturer, is reporting financial and operating results for the third quarter ended September 30, 2025. “Q3 2025 was a quarter of steady progress and operational strengthening as we continued to position Sow Good for long-term sustainable growth,” said Claudia Goldfarb, CEO of Sow Good. “The decisive actions we’ve taken over the past several months have simplified our footprint, reduced fixed costs, and enhanced efficiency across the organization. We’ve now completely vacated our Mockingbird facility, reducing our footprint by over 50,000 square feet and delivering immediate savings, and we will fully vacate our Rock Quarry facility by the end of January, reducing our footprint by more than...

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 30, 2025. Recent Corporate HighlightsRecord ReWalk: Q3 marked Lifeward’s second consecutive record quarter for Medicare beneficiary placements...

Quarterly revenue of $128.4 million, up 1% from Q2 and up 5% from a year ago Quarterly operating profit of $3.8 million, up 19% from Q3 2024TAIPEI, Taiwan, Nov. 14, 2025 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (“APWC” or the “Company”) (NASDAQ: APWC) today reported unaudited results for the third quarter ended September 30, 2025. Quarterly revenue was $128.4 million, up 1% from the previous quarter and up 5% from a year ago. Copper unit volume, measured by the tonnage of copper contained in the wire and cable sold, increased 2% in the third quarter from Q2 and increased 12% from a year ago. This does not include other raw materials, such as aluminum and insulation materials. For the quarter, earnings per share were $0.05, up 67% from the previous quarter and down 17% from...

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in-disease durability and tolerability in BOND-003 Cohort C with robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with HR NMIBC unresponsive to Bacillus Calmette Guerin (BCG) Completed enrollment of PIVOT-006, one of the largest randomized Phase 3 studies in intermediate risk (IR) NMIBC encompassing broadest range of patients per AUA/SUO Guidelines Well-positioned to deliver on key milestones with $680.3 million cash and cash equivalents and marketable securities sufficient to fund operations into the first half of 2028IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE)...